Sunshine Lake Pharma wins FDA approval for first Chinese interchangeable biosimilar
Updated
Updated · China Daily · May 6
Sunshine Lake Pharma wins FDA approval for first Chinese interchangeable biosimilar
11 articles · Updated · China Daily · May 6
Its Langlara insulin glargine can be substituted for Sanofi's Lantus in the US without a new prescription and becomes the fourth insulin glargine product on that market.
The approval covers adults and children with Type 1 diabetes and adults with Type 2 diabetes, backed by a 104-subject Phase I study and a 2025 FDA factory inspection.
Sunshine Lake partnered with US distributor Lannett, which has secured an initial order of at least 18 million units over 18 months, as Chinese drugmakers push deeper into regulated global markets.
With China's first interchangeable insulin approved, how will it reshape the future of America's drug supply?
Past biosimilars struggled in the US. Can this first-ever Chinese insulin finally disrupt the market?
FDA Grants Interchangeable Biosimilar Approval to LANGLARA, Paving the Way for Affordable Insulin Access in 2026
Overview
In early 2026, the FDA approved LANGLARA, an interchangeable biosimilar to Lantus, developed by Sunshine Lake Pharma and partners. This approval, supported by extensive clinical trials and a successful FDA inspection of Sunshine Lake's large-scale manufacturing facility, enables Lanexa Biologics to commercialize LANGLARA in the U.S. market. Its interchangeable status allows pharmacists to substitute it without prescriber approval, introducing significant price competition that challenges established insulin makers like Novo Nordisk and Eli Lilly. Beyond the U.S., this FDA validation accelerates Sunshine Lake's global expansion into emerging markets. However, adoption faces hurdles from payer policies and patient acceptance, which will shape LANGLARA's impact on insulin affordability and access.